Why TheranosticTrials.org?

The leading global platform for radiopharmaceutical & molecular imaging clinical trials

Global Reach

We are uniquely positioned at the heart of Theranostics.

Increasing Awareness

We're dedicated to increasing awareness about Theranostics and it's potential.

Fostering Engagement

We encourage active participation in the Theranostics community.

Building Connections

We connect physicians, clinics, and patients with Theranostic opportunities.

Comprehensive Resources

Access a complete list of cancer Theranostic Trials and educational materials.

Advancing the Field

We collaborate with key opinion leaders to push Theranostics forward.

Our Ultimate Goal

Provide more hope to cancer patients everywhere!


Navigating Tips

Pick Your Path


Stats

Therapeutic Theranostic Research Report

Source: Oppenheimer & Co. Research

View All


Isotopes

View details about the isotopes used in the trials listed on our site!

Learn more
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
SAMARIUM-153
Radioisotope: Sm153
Theranostic Role: Therapeutic
T1/2 (Half-Life): 1.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Max 808 keV Gamma: 103 keV (28%)
Range: 0.6 mm
Decay Daughters: Eu153 (Stable)
Status: FDA Approval: QUADRAMET® (1997)
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s

DI Badge

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Luke T. Nordquist, MD

Dr. Luke Nordquist is a Medical Oncologist with an expertise in Prostate Cancer. He is the Founder and CEO of XCancer® in Omaha, NE. Dr. Luke and the XCancer® team are globally recognized for their many contributions to the advancement of novel imaging and therapies for prostate cancer. The XCancer® team are often considered as a go to site for rapid startup, phase 1 trials because of their focus, quality and exceptional efficiency. XCancer® has the ability to open a clinical trial in a few weeks. As of 2024, Dr. Luke and his team have accrued more than 1500 patient to clinical trials and conducted more than 20 First-in-World clinical trials for Prostate Cancer. They have extensive experience with many radioisotopes having conducted more than 40 radiopharmaceutical imaging and therapeutic trials. His team accrued the first patient, the most patients and had the highest quality data on the Lu177 PSMA Vision Trial. More than 450 prostate cancer patients every month from more than 40 states and several countries travel to Dr. Luke in Omaha for their prostate cancer care. To improve education, awareness, and access to radiopharmaceutical clinical trials globally, Dr. Luke developed TheranosticTrials.org. XCancer® also has developed a strategic program, business knowledge, and training curriculum to assist other Medical Oncologists & Community Cancer Centers from coast to coast in developing radiopharmaceutical programs that are able to conduct early to late phase clinical trials. XCancer® is helping assist cancer care as far away as Tanzania, Africa. The XCancer® Foundation, funded the construction of a cancer housing hostel at the Kilimanjaro Christian Medical Center (KCMC) in Moshi, Tanzania. Omaha, NE USA Contact Information: For Patient Appointments: Patient Advocate Desk: 402-991-8468 For Clinical Trials: Tony Romero 402-991-8468 For Industry/Business Meetings: Stacy Moore 402-991-8468 drluke@xcancer.com

Read More >>

See All Investigators

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

  1. Cancer Targets
  2. Ligand (demonstrated as the Truck GPS set to find a specific Target)
  3. Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
  4. Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
  5. Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
  6. Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.

View RLT Components

Education


banana

Sponsors

blueearththerapeuticsltdportlandinvestmentcounselurotodayblueearthdiagnosticsltdadvancedacceleratorapplicationsbayertelixpharmaceuticalsfusionpharmaceuticalsincclaritypharmaceuticalscuriumpointbiopharmajanssenpharmaceuticalsratiotherapeuticsincartbionorthstarnucleusradiopharmaspagonanomedicalabradiopharmtheranosticsprostatecancerfoundationperspectivetherapeuticsinvenraconvergenttherapeuticsterrapowerisotopesnusanorlsradiopharmacieslantheusmedicalimaging
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468